申请人:AGIOS PHARMACEUTICALS, INC.
公开号:US20210323944A1
公开(公告)日:2021-10-21
Provided are formulations of ivosidenib including a number of polymorphs. Further provided are formulations of ivosidenib containing a number of known impurities. Still further provided are stable compositions of ivosidenib.